July 27, 2014 | Atox Bio, an Israeli company developing therapeutics for serious infections, announced that it raised $23 million in an investment round led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The funds will be used by Atox Bio to begin late stage clinical trials of AB1o3, a therapy treatment for Necrotizing Soft Tissue Infections or “flesh-eating bacteria,” as well as other serious infections. The AB103 immunomodulator was discovered by Prof. Raymond Kaempfer and Dr. Gila Arad.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments